Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

New approach identifies epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment

Many new anti-cancer drugs inhibit proteins that are essential for the proliferation of cancer cells. One example is ibrutinib, an innovative therapy for chronic lymphocytic leukemia first approved in 2014.

29 Jan 2019

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

FDA approves new combination therapy for acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.

30 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Barcelona researchers win one of the most prestigious EU grants to study CLL

The European Research Council today announced the results of the 2018 Synergy Grants call for proposals. The aim of Synergy Grants is to address ambitious research questions that can only be answered by the coordinated work of a small group of two to four principal investigators and their teams, bringing together their complementary skills, knowledge and resources.

26 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

New study links stress with biological disease markers in leukemia patients

Patients with chronic lymphocytic leukemia who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease.

12 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

Patients with chronic lymphocytic leukemia have higher risk of melanoma, shows study

While studying a large group of individuals with chronic lymphocytic leukemia, a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer.

10 Aug 2018

Portfolio diet reduces risk factors for cardiovascular disease

University of Toronto researchers have found that the portfolio diet, a plant-based way of eating previously shown to lower cholesterol levels, reduces other risk factors for cardiovascular disease including blood pressure, triglycerides and inflammation.

27 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.

17 Jul 2018

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase occupancy assay that can measure target engagement in peripheral blood mononuclear cells and in lymph-node and bone-marrow samples.

17 Jul 2018

New findings refine link between clonal hematopoiesis and blood cancer risk

It's a common occurrence in elderly people: Blood cells carrying mutated DNA explosively increase in number, resulting in genetic "mosaicism": the presence of a population of cells that carries an altered genome.

12 Jul 2018

Chronic Lymphocytic Leukemia News and Research

Further Reading

New approach identifies epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment

New strategies may improve performance of CAR-T cell therapy in treating cancer

FDA approves new combination therapy for acute myeloid leukemia

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Barcelona researchers win one of the most prestigious EU grants to study CLL

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

New study links stress with biological disease markers in leukemia patients

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Patients with chronic lymphocytic leukemia have higher risk of melanoma, shows study

Portfolio diet reduces risk factors for cardiovascular disease

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

New findings refine link between clonal hematopoiesis and blood cancer risk

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News